Comparison of the content of selected heavy metals in the liver tissue of the wild boar (Sus scrofa), red fox (Vulpes vulpes) and red deer (Cervus elaphus), living in north-eastern Poland.

The study aimed to determine the content of selenium (Se), zinc (Zn), copper (Cu) and cadmium (Cd) in the liver of predominantly plant-eating omnivore wild boar (Sus scrofa), predominantly meat-eating omnivore red fox (Vulpes vulpes) and herbivore red deer (Cervus elaphus), from North-Eastern Poland (Warmia and Mazury), in order to verify the distribution of these elements in the trophic pyramid. Furthermore, the study was used to assess the risk of eating venison. Samples were analyzed using atomic absorption spectrophotometry. The average concentration of Se was 3.9 (p⟨0.001) and 1.8-fold higher (p0.001) in the wild boar and red fox, respectively, in comparison to the red deer, and 2.1-fold higher in the wild boar comparing to the red fox (p⟨0.001). There was no difference in the average concentration of Zn. The average concentration of Cu was 9.3. Concentration of this element was 5.4-fold higher in red deer in comparison to red fox (p⟨0.001) and 9,34-fold higher than in wild boar (p⟨0.001). The average concentration of Cd was 1.9-fold higher in wild boar in comparison to the red fox (p⟨0.029). Correlation between Cu and Cd concentrations was also observed in the case of the red deer and red fox, while no such correlations were observed between the tested elements in the wild boar. In conclusion, the liver concentrations of these heavy metals in selected wild animas species from the hunting areas of Warmia and Mazury, do not exceed standard safe values for consumers. Moreover, the wild red deer population in North-Eastern Poland is significantly Se deficient.

The influence of selenium and vitamin E supplementation on cytological assessment of red blood cell line of bone marrow in fallow deer kept in captivity.

Cytological evaluation of bone marrow smears stained by May-Grünwald Giemsa method was performed. The smears came from 20 fallow deer (Dama dama) 3 days old divided into 2 groups each consisting of 10 animals. The experimental group (E) received intramuscularly selenium and vitamin E at a dose of 3.0 ml (tocopherol acetate - 50 mg, sodium selenite - 0.5 mg, solvent - 1 ml) in the 3rd day of age. The control group (C) did not receive any supplementation or placebo. For hematological analyzes blood was collected three times: on 0, 15th and 25th day of the experiment. Serum concentration of selenium and vitamin E was determined using high perfor- mance liquid chromatography and glutathione peroxidase activity (GSH-Px) by kinetic method. On the 15th day after supplementation, a statistically significant increase in the percentage of erythroblastic cell line was observed in bone marrow smears. At that time, the increase in GSH-Px activity in the E group was also observed, reaching the value of 165.3 U/gHb, which was statisti- cally significant. The percentage of proerythroblasts (8.23% in group E and 5.02% in group C) differed significantly between groups at the 25th day after supplementation. This study revealed that supplementation of selenium and vitamin E resulted in an increase in the number of erythro- cytes to an average of 13.5 (˟ 10¹²/l) in the experimental group on 25th day with a significant increase in hemoglobin to 193 g/l in the experimental group.

Influence of simvastatin on red blood cell line in porcine bone marrow.

Simvastatin is a drug commonly used to reduce the cholesterol level. 32 clinically healthy female pigs with a bodyweight of 35-40 kg, kept in standard laboratory conditions were chosen for the experiment and divided into 2 groups (control and experimental) consisting of 16 animals. The experimental group received simvastatin orally at a dose of 40 mg (one tablet once a day) for 56 days, and at the same time the control group received placebo (empty gelatin capsules). Bone marrow smears and peripheral blood samples were evaluated. The obtained results indicate that simvastatin may inhibit erythropoiesis even after a relatively short period of administration, and observed changes can be the cause of some symptoms (for example anemia) occurring during statin therapy.